

# Financial Tear Sheet

## Primary IR Contact

Ed Bell  
T +1 206-272-4345  
invest@ctibiopharma.com  
(mailto:invest@ctibiopharma.com)

## Transfer Agent

### Computershare

Mail:  
Computershare Investor Services  
P.O. Box 43078  
Providence, RI 02940-3078

Overnight Delivery:  
Computershare Investor Services  
250 Royall Street  
Canton, MA 02021  
United States of America

T: 312-588-4187  
F: 312-601-4332  
www.Computershare.com  
(http://www.computershare.com)

## Corporate Profile

CTI BioPharma Corp. is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies covering a spectrum of blood-related cancers that offer a unique benefit to patients and healthcare providers. CTI BioPharma has a commercial presence in Europe and a late-stage development pipeline, including pacritinib, CTI BioPharma's lead product candidate, which is currently being studied in a Phase 3 program for the treatment of patients with myelofibrosis. CTI BioPharma is headquartered in Seattle, Washington, with offices in London and Milan under the name CTI Life Sciences Limited.

## Stock Performance: CTIC (Nasdaq)

Exchange NASDAQ CM (US Dollar)

Price **\$0.94**

Change  
(%) ▼ 0.01 (1.05%)

Volume 209,404

52 Week Low \$0.60

Market Cap \$54,920,967

Rolling EPS -0.86

PE Ratio 0

Shares Outstanding 57,988,562

Data as of 02/19/19 12:27 p.m. ET



## Recent Headlines & Events

Feb 11, 2019 - 7:00 a.m.

CTI BioPharma Receives \$10 Million  
Milestone Payment for TRISENOX®  
([phoenix.zhtml?c=92775&p=irol-  
newsArticle&ID=2386868](http://phoenix.zhtml?c=92775&p=irol-newsArticle&ID=2386868))

There are currently no events scheduled.

Feb 01, 2019 - 7:01 a.m.

CTI BioPharma Receives Results of the  
CHMP Oral Explanation for Pacritinib in the  
Treatment of Myelofibrosis and Provides  
Development Update  
([phoenix.zhtml?c=92775&p=irol-  
newsArticle&ID=2385717](http://phoenix.zhtml?c=92775&p=irol-newsArticle&ID=2385717))

Dec 28, 2018 - 7:00 a.m.

CTI BioPharma Announces Completion of  
Enrollment in the Phase 2 PAC203 Study of  
Pacritinib ([phoenix.zhtml?c=92775&p=irol-  
newsArticle&ID=2381686](http://phoenix.zhtml?c=92775&p=irol-newsArticle&ID=2381686))

## Ownership Summary

### Shareholders

	<b>Holders</b>	<b>Value (\$MM)</b>	<b>% O/S</b>	<b>Shares</b>
Institution	105	28.13	61.9	35,880,823
Mutual Fund	109	5.62	8.5	4,923,755
Insider *	4	.48	0.3	168,978

*\*Insider values reflect direct beneficial ownership.*

### Top Holders

	<b>Shares Held</b>	<b>% O/S</b>	<b>Share Change</b>	<b>Filing Date</b>
BVF Partners L.P.	6,929,690	12.0	0	12/31/18
Stonepine Capital Management, LLC	5,726,579	9.9	424,516	12/31/18
OrbiMed Advisors, LLC	5,000,000	8.6	0	12/31/18
New Enterprise Associates (NEA)	3,750,000	6.5	0	12/31/18
BlackRock Institutional Trust Company, N.A.	2,600,445	4.5	-32,134	12/31/18
The Vanguard Group, Inc.	1,502,494	2.6	-885,336	12/31/18
Opaleye Management Inc.	1,400,000	2.4	-150,000	12/31/18
Renaissance Technologies LLC	1,087,249	1.9	325,688	12/31/18
State Street Global Advisors (US)	922,844	1.6	66,326	12/31/18
Balyasny Asset Management LP	922,655	1.6	622,655	12/31/18

*Data provided by Nasdaq. Minimum 15 minutes delayed.*